Physician profile
Jared Vincent
NPI 1639167836
$4,973.15
in general payments reported to CMS, 2019-2025
22 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $219 · 2021: $424 · 2022: $919 · 2023: $1,046 · 2024: $706 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,073.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,346.35 | 2019-2025 | Idosetr, Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Alcon Vision LLC | $1,225.42 | 2022-2025 | Clareon, Rocklatan, Clareon Panoptix Pro |
| Ocular Therapeutix, INC. | $407.58 | 2022-2025 | Dextenza |
| Allergan, INC. | $376.19 | 2019-2022 | |
| Abbvie INC. | $370.45 | 2022-2025 | Xen Glaucoma Treatment System, Durysta |
| Johnson & Johnson Surgical Vision, INC. | $297.71 | 2020-2025 | Tecnis Simplicity, Catalys System |
| Bausch & Lomb Americas INC. | $189.04 | 2022-2025 | Vyzulta |
| Tarsus Pharmaceuticals, INC. | $144.51 | 2025 | Xdemvy |
| Iridex Corporation | $115.70 | 2022-2023 | |
| Dompe US, INC. | $99.75 | 2023-2025 | Oxervate |
| Biotissue Holdings INC. | $68.81 | 2023-2025 | |
| Oyster Point Pharma, INC. | $54.82 | 2022-2023 | Tyrvaya |
| New World Medical,INC. | $52.50 | 2019 | |
| Sight Sciences, INC. | $40.78 | 2022-2023 | Omni Surgical System |
| Horizon Therapeutics Plc | $33.32 | 2022-2023 | Tepezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $24.78 | 2020 | |
| Eyevance Pharmaceuticals LLC | $22.56 | 2022 | |
| Merz Pharmaceuticals, LLC | $22.23 | 2025 | Xeomin |
| Amgen INC. | $21.30 | 2024 | Tepezza |
| Mallinckrodt Hospital Products INC. | $21.05 | 2024 | Acthar |
| Harrow Eye, LLC | $20.53 | 2024 | Vevye |
| Vyera Pharmaceuticals, LLC | $17.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Vincent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.